Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
Latest newsMore news →
Sawai Pharmaceutical and Towa Pharmaceutical, the two major generic drugmakers under Sawai Group Holdings, are increasing production and supply of the anti-influenza generic oseltamivir in response to an unusually early flu season.3d agoTowa Pharmaceutical announced it received additional regulatory approval for its lenalidomide capsules 2.5mg/5mg 'TOWA', expanding the indications to include relapsed or refractory follicular lymphoma and marginal zone lymphoma, along with corresponding dosage and administration.26d agoTowa Pharmaceutical announced on August 17 that it obtained manufacturing and marketing approval for 18 generic drug products across 7 ingredients, including first-time approvals for 4 ingredients such as guanfacine extended-release tablets for ADHD and linagliptin tablets for type 2 diabetes.34d ago